Compare ARE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARE | UTHR |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 20.3B |
| IPO Year | 1997 | 1999 |
| Metric | ARE | UTHR |
|---|---|---|
| Price | $45.56 | $489.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 12 |
| Target Price | $69.38 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 2.9M | 424.3K |
| Earning Date | 01-26-2026 | 10-29-2025 |
| Dividend Yield | ★ 10.29% | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | N/A | ★ 26.38 |
| Revenue | $3,058,395,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | N/A | $13.64 |
| Revenue Next Year | N/A | $5.78 |
| P/E Ratio | ★ N/A | $18.55 |
| Revenue Growth | N/A | ★ 13.50 |
| 52 Week Low | $45.47 | $266.98 |
| 52 Week High | $107.19 | $492.62 |
| Indicator | ARE | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 25.29 | 68.10 |
| Support Level | $52.39 | $470.13 |
| Resistance Level | $54.17 | $492.62 |
| Average True Range (ATR) | 1.84 | 10.72 |
| MACD | 0.30 | -0.53 |
| Stochastic Oscillator | 0.06 | 89.55 |
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.